Table 4.
MicroRNAs for differential diagnosis of various CTCL subtypes.
| CTCL subtype | miRNAs | Expression | Significance | Study |
|---|---|---|---|---|
| CTCLs | miRNA classifier: miR-155, miR-203, miR-205 | miR-155 overexpressed, miR-203 and miR-205 repressed | Differentially diagnose CTCLs from other benign inflammatory skin disorders | Ralfkiaer et al. (124) |
| miRNA classifier: miR-155, miR-130b, miR-142-3p, miR-200b, and miR-203 | miR-200b and miR-203 are repressed rest miRNAs overexpressed | Diagnose CTCLs from benign inflammatory dermatosis (BID) | Shen et al. (125) | |
| miRNA classifier: miR-106b-5p, miR-148a-3p, miR-338-3p | Differentially expressed (over) | The diagnostic and predictive significance associated with progression from low risk to high risk | Lindahl et al. (126) | |
| Mycosis fungiodes | miRNA classifier: miR-26a, miR-222, miR-181a, miR-146a | Differentially expressed in inflammatory skin diseases, MF plaques, and MF tumors | Differentially expressed in MF plaques, MF tumors, and inflammatory skin disorders | Manso et al. (121) |
| let-7a, let-7d, let-7f | Underexpression | Low expression in metastatic MF | Maj et al. (127) | |
| miR-155, miR-92a, miR-93 | Upregulated | Upregulation in tumor MF (miR-93 most upregulated) | van Kester et al. (123) | |
| miR-93 | Downregulation | miR-93 associated with early MF | Talaat et al. (128) | |
| miR-155 and miR-203/miR-205 | Upregulated miR-155 and downregulated miR-203/miR-205 | Differentiate CTCLs from other malignancies | Dusílková et al. (129) | |
| miR-34a, miR-93-5p, miR-181a, miR-181b | Upregulated | Differentiate MF from others | Marosvári et al. (130) | |
| 39 miRNA group: miR-142-3p, miR-150-5p, miR-146b-5p, miR-483-3p, miR-940, miR-766-3p, miR-29a-3p, miR-342-3p, miR-128-3p, miR-484, miR-32-5p, miR-425-5p, miR-424-5p, miR-433-3p, miR-625-3p, miR-181c-5p, miR-29b-3p, miR-138-5p, miR-26a-2-3p, miR-877-5p, miR-517a-3p, miR-542-5p, miR-874-3p, miR-539-5p, miR-34c-5p, miR-29c-3p, miR-185-5p, miR-425-3p, miR-215-5p, miR-503-5p, miR-652-3p, miR-449a, miR-181d-5p, miR-627-5p, miR-135a-5p, miR-642a-5p, miR-454-3p, miR-30a-5p, miR-196a-5p | Differentially expressed | Exclusively expressed in early MF and not in psoriasis | Sørensen et al. (131) | |
| hsa-miR-423-5p, hsa-miR-361-3p, hsa-miR-652-3p, hsa-miR-484, hsa-miR-766-3p, hsa-miR-142-3p, hsa-miR-142-5p, hsa-miR-21-5p, hsa-miR-146a-5p, hsa-miR-155-5p, hsa-miR-21-3p, hsa-miR-93-5p, hsa-miR-425-5p, hsa-miR-130b-3p, hsa-miR-223-3p, hsa-miR-146b-5p, hsa-miR-185-5p, hsa-miR-150-5p, hsa-miR-342-3p, hsa-miR-345-5p, hsa-miR-22-3p, hsa-miR-15a-5p, hsa-miR-34a-5p, hsa-miR-29c-3p, hsa-miR-29a-3p, hsa-miR-22-5p, hsa-miR-424-5p, hsa-miR-7-5p, hsa-miR-18a-5p, hsa-miR-18b-5p, hsa-miR-128-3p, hsa-miR-352-5p, hsa-miR-454-3p, hsa-miR-1248, hsa-miR-16-1-3p, hsa-miR-181a-3p, hsa-miR-501-5p, hsa-miR-326, hsa-miR-425-3p, hsa-miR-340-5p, hsa-miR-424-3p, hsa-miR-503-5p, hsa-miR-32-5p, hsa-miR-495-3p, hsa-miR-377-3p, hsa-miR-127-5p, hsa-miR-381-3p, hsa-miR-337-5p, hsa-miR-376b-3p, hsa-miR-188-5b, hsa-miR-154-3p, hsa-miR-431-5p, hsa-miR-215-5p, hsa-miR-301a-3p, hsa-miR-450a-5p, hsa-miR-629-5p, hsa-miR-330-3p, hsa-miR-9-3p, hsa-miR-33b-5p, hsa-miR-642a-5p, hsa-miR-138-5p, 34c-5p, hsa-miR-18a-3p, hsa-miR-370-3p, hsa-miR-671-5p, hsa-miR-874-3p, hsa-miR-30b-3p, hsa-miR-584-5p, 31-5p, hsa-miR-31-3p, hsa-miR-663a, hsa-miR-483-3p, hsa-miR-940, hsa-miR-433-3p, hsa-miR-410-3p, hsa-miR-212-3p, hsa-miR-26a-2-3p, hsa-miR-517a-3p, hsa-miR-34b-3p, hsa-miR-625-3p, hsa-miR-487b-3p, hsa-miR-539-5p, hsa-miR-181c-5p, hsa-miR-181d-5p, hsa-miR-522-5p, hsa-miR-373-3p, hsa-miR-193a-3p, hsa-miR-329-3p, hsa-miR-627-5p, hsa-miR-135b-5p, hsa-miR-135a-5p, hsa-miR-346, hsa-miR-449a, hsa-miR-589-5p, hsa-miR-877-5p, hsa-miR-509-3p, hsa-miR-598-3p, hsa-miR-187-3p | Upregulated | Upregulated in early MF plaque lesions vs. healthy controls | Sørensen et al. (131) | |
| 10 miRNAs: hsa-miR-204-5p, hsa-miR-375, hsa-miR-99a-5p, hsa-miR-125b-5p, hsa-miR-30a-3p, hsa-miR-10b-5p, hsa-miR-10a-5p, hsa-miR-338-5p, hsa-miR-149-5p, hsa-miR-196a-5p | Downregulated | Downregulated in early MF plaques lesions vs. healthy controls | Sørensen et al. (131) | |
| 81 miRNAs: hsa-miR-188-5p, hsa-miR-517a-3p, 34b-3p, hsa-miR-16-1-3p, hsa-miR-142-3p, hsa-miR-155-5p, hsa-miR-146a-5p, hsa-miR-21-5p, hsa-miR-15a-5p, hsa-miR-425a-5p, hsa-miR-130b-3p, hsa-miR-21-3p, hsa-miR-18b-5p, hsa-miR-223-3p, hsa-miR-146b-5p, hsa-miR-363-5p, hsa-miR-34a-5p, hsa-miR-29a-3p, hsa-miR-345-5p, hsa-miR-181a-3p, hsa-miR-18a-3p, hsa-miR-484, hsa-miR-150-5p, hsa-miR-343-3p, hsa-miR-766-3p, hsa-miR-326, hsa-miR-7-5p, hsa-miR-1248, hsa-miR-874-3p, hsa-miR-18a-5p, hsa-miR-301a-3p, hsa-miR-501-5p, hsa-miR-187-3p, hsa-miR-433-3p, hsa-miR-424-3p, hsa-miR-625-3p, hsa-miR-30b-3p, hsa-miR-330-3p, hsa-miR-212-3p, hsa-miR-181d-5p, hsa-miR-128-3p, hsa-miR-423-5p, hsa-miR-361-3p, hsa-miR-26a-2-3p, hsa-miR-483-3p, hsa-miR-214-5p, hsa-miR-9-3p, hsa-miR-127-5p, hsa-miR-154-3p, hsa-miR-663a, hsa-miR-381-3p, hsa-miR-31-5p, hsa-miR-31-3p, hsa-miR-495-3p, hsa-miR-940, hsa-miR-181c-5p, hsa-miR-340-5p, hsa-miR-337-5p, hsa-miR-887-3p, hsa-miR-542-5p, hsa-miR-877-5p, hsa-miR-329-3p, hsa-miR-671-5p, hsa-miR-346, hsa-miR-615-3p, hsa-miR-370-3p, hsa-miR-33b-5p,-376b-3p, hsa-miR-193a-3p, hsa-miR-509-3p, hsa-miR-598-3p, hsa-miR-135b-5p, hsa-miR-602, hsa-miR-584-5p, 34c-5p, hsa-miR-654-5p, hsa-miR-22-5p, hsa-miR-629-5p, hsa-miR-539-5p, hsa-miR-373-3p | Upregulated | Upregulated in early MF patch lesions vs. healthy controls | Sørensen et al. (131) | |
| 9 miRNAs: hsa-miR-204-5p, hsa-miR-99a-5p, hsa-miR-30a-5p, hsa-miR-10b-5p, hsa-miR-30a-3p, hsa-miR-375, hsa-miR-338-3p, hsa-miR-10a-5p, hsa-miR-125b-2-3p | Downregulated | Downregulated n early MF patch lesions vs. healthy controls | Sørensen et al. (131) | |
| 13 miRNAs: hsa-miR-139-3p, hsa-miR-199a-5p, hsa-miR-127-3p, hsa-miR-196a-5p, -142-5p, hsa-miR-21-5p, hsa-miR-21-3p, 223-3p, hsa-miR-18a-5p, hsa-miR-22-5p, 322-3p, hsa-miR-32-5p, hsa-miR-766-3p | Differentially expressed | Early MF plaque lesions and patch lesions | Sørensen et al. (131) | |
| LCT-MF | miR-155, miR-223 | Overexpressed in FMF | Differentiate FMF from LCT-MF | Marosvári et al. (130) |
| miR-181b, miR-326 | Overexpressed in LCT-MF | Differentiate FMF from LCT-MF | Marosvári et al. (130) | |
| miR-21-3p, miR-146a-3p, miR136-5p, miR-889, and miR-539-3p | Overexpressed in LCT-MFs | Differentiates LCT-MFs from non-LCT-MFs | Di Raimondo et al. (132) | |
| miR-708-5p, miR-5701, and miR-3653 | Downregulated in LCT-MFs | Differentiates LCT-MFs from non-LCT-MFs | Di Raimondo et al. (132) | |
| Sezary syndrome (SS-MF) | miR-15a, miR-16, miR-150, miR-191 along with miR-223, and miR-17-5p | Overexpressed in SS-MFs | Differentiates SS-MFs from non-SS-MFs | Ballabio et al. (133) |
| miR-155 | Overexpression in SS-MFs | Higher expression in SS-MF than in MF | Fava et al. (134) | |
| miR-22-3p, miR-199a-3p, mi-R-199a-5p, miR-199b-5p | Overexpression | Overexpression in SS-MF and eMF compared to early-stage MF | Rittig et al. (135) | |
| miR-433-3p, miR-27b-5p, miR-663a, miR-342-3p, miR-484, miR-328-3p, and miR-483-3p | Lower expression | Lower expression in SS-MF and eMF compared to early-stage MF | Rittig et al. (135) |